28.94 +0.36 (1.25%)
After hours: 4:11PM EST
|Bid||27.50 x 900|
|Ask||28.60 x 800|
|Day's Range||28.49 - 29.43|
|52 Week Range||9.51 - 31.90|
|Beta (5Y Monthly)||2.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 18, 2020 - Feb 23, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.71|
Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.
Momenta's proposed inflammatory blood disease therapy, M254, could provide an alternative to the current, IV-based treatment, with a potential market of $6 billion, according to a JPMorgan analyst.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today provided a 2019 year-end corporate update and key anticipated milestones for 2020. Five of six ITP patients administered M254 (43 mg/kg to 250 mg/kg) responded and exhibited platelet counts =50 x 109/L.
CAMBRIDGE, Mass., Jan. 03, 2020 -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) (“Momenta” or the “Company”), a biotechnology company focused on discovering and developing.
Momenta Pharmaceuticals, Inc. (MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2020 at 3:00 p.m. PT (6:00 p.m. ET). Following the presentation, management will participate in a question and answer session at 3:30 p.m. PT (6:30 p.m. ET).
Momenta Pharmaceuticals, Inc. (MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors. “Dr. Barlow’s expertise in market access and commercial pricing will be invaluable as we continue to develop our pipeline of novel autoimmune therapeutics,” said Craig Wheeler, President and Chief Executive Officer at Momenta Pharmaceuticals.
Momenta has granted the underwriters an option to purchase up to an additional 2,177,419 shares of its common stock, exercisable for 30 days. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering. The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on August 8, 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
Is Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
Momenta Pharmaceuticals, Inc. (MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock. Momenta also expects to grant the underwriters of the offering an option to purchase up to an additional $30,000,000 of shares of its common stock, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Momenta.
We'd be surprised if Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shareholders haven't noticed that the Chief Medical...
Momenta Pharmaceuticals, Inc. (MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the upcoming 61st American Society of Hematology (ASH) Annual Meeting and Exposition being held in Orlando, FL from December 7-10, 2019.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will webcast its presentation at two upcoming investor conferences. A webcast of the presentations will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. Momenta Pharmaceuticals is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio.
Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 39.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., Oct. 31, 2019 -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Momenta (MNTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the third quarter ended September 30, 2019 before the U.S. financial markets open on Thursday, October 31, 2019. Management will host a conference call on October 31, 2019 at 8:30 a.m. ET to discuss these results and provide an update on the company. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com.
“We are excited to have Dr. Grogan join our Board. She has led numerous investigational new drug applications and marketing authorization applications, and has extensive experience with international regulatory authorities,” said Craig Wheeler, President and Chief Executive Officer at Momenta Pharmaceuticals. “I am honored to join Momenta’s Board of Directors as the team makes strides in addressing the needs of patients with rare autoimmune diseases,” adds Dr. Donna Grogan.
Craig Wheeler became the CEO of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) in 2006. First, this article will compare...